Skip to main content
Pharmicell Co.,Ltd. logo

Pharmicell Co.,Ltd. — Investor Relations & Filings

Ticker · 005690 ISIN · KR7005690003 KO Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2020-07-17 Major Shareholding Noti…
Country KR South Korea
Listing KO 005690

About Pharmicell Co.,Ltd.

https://www.pharmicell.com/eng/

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Recent filings

Filing Released Lang Actions
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for the company Pharmicell. It details specific changes in share ownership by the major shareholder (Kim Hyun-soo) due to gifts and off-market sales. This type of filing is a standard regulatory requirement for reporting changes in major shareholdings, which falls under the 'Major Shareholding Notification' category.
2020-07-17 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (e.g., Kim Hyun-soo and others). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes.
2020-07-17 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) where company insiders (directors/major shareholders) report changes in their personal shareholdings. This falls under the 'Director's Dealing' category as it details personal share transactions by a company executive (Kim Hyun Soo).
2020-07-17 Korean
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a single sales and supply contract (단일판매ㆍ공급계약 체결) by Pharmicell. It details the contract value, the counterparty (Sigma-Aldrich), the product (Nucleosides), and the contract period. Since this is a specific regulatory disclosure regarding a business transaction that does not fit into the other specialized categories like M&A or financial reports, it is classified as a general regulatory filing.
2020-06-03 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) filed by Pharmicell. It details specific changes in share ownership by individuals related to the company (major shareholders and executives). This type of filing is specifically categorized as 'Director's Dealing' (DIRS) in the provided schema, as it reports insider transactions and changes in ownership status for key individuals.
2020-06-01 Korean
단일판매ㆍ공급계약체결
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) between Pharmicell and Thermo Fisher Scientific. It details the contract value, duration, and counterparty. Since this is a specific regulatory disclosure regarding a commercial contract and does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2020-05-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.